eHIV Review

Two Drugs — The New ART Paradigm?

In this issue:

The current gold standard for HIV treatment — triple drug therapy — is evolving. Dual drug regimens — two drugs from two separate classes — are becoming the new consensus. But which agents are most appropriate for patients starting initial treatment? Which should be used for those currently virologically suppressed and wanting to switch for regimen simplification? What does the evidence say, and what do the experts recommend?

In this issue, Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzes the current research and provides answers to help guide these important decisions.

Learning objectives:

• Explain the appropriate use of dolutegravir-containing two-drug regimens in ART-naïve individuals with HIV or as switch regimens in individuals who are already virologically suppressed. 
• Describe the clinical situations where dual therapy should NOT be used.